SAN DIEGO, January 2, 2019 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on metabolic diseases, announced today a presentation on the use of non-invasive imaging tools in NASH trials, to be presented at the NASH-TAG Conference January 3-5 in Park City, Utah.
The poster presentation is titled Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Non-alcoholic Fatty Liver Disease (NAFLD).
The data to be presented evaluates the use of controlled attenuation parameter (CAP) as a screening tool for identifying patients with non-alcoholic fatty liver disease.
About ProSciento, Inc.
ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.prosciento.com.
For inquiries, please contact:
Carine Beysen, DPhil
Senior Director, Clinical Research Innovation, ProSciento, Inc.
Carine.Beysen@prosciento.com
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
abby.devine@prosciento.com
